Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) went down by -4.96% from its latest closing price when compared to the 1-year high value of $71.11 and move down -28.03%, while DCPH stocks collected -17.07% of loss with the last five trading sessions. Press Release reported on 02/13/20 that Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Worth an Investment?
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) of the analysts out of 0 who provided ratings for Deciphera Pharmaceuticals, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $66.77 which is $11.23 above current price. DCPH currently has a short float of 8.12% and public float of 31.54 M with average trading volume of 539.87K shares.
DCPH Market Performance
DCPH stocks went down by -17.07% for the week, with the monthly drop of -15.05% and a quarterly performance of 14.00%, while its annual performance rate touched 98.57%. The simple moving average for the period of the last 20 days is -16.14% for DCPH stocks with the simple moving average of 41.57% for the last 200 days.
Analysts’ Opinion on Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Many brokerage firms have already submitted their reports for DCPH stocks, with Jefferies repeating the rating for DCPH shares by setting it to “Buy”. The predicted price for DCPH socks in the upcoming period according to Jefferies is $77 based on the research report published on December 20, 2019.
SVB Leerink, on the other hand, stated in their research note that they expect to see DCPH stock at the price of $34, previously predicting the value of $29. The rating they have provided for DCPH stocks is “Mkt Perform” according to the report published on October 29, 2019.
JMP Securities gave “Mkt Outperform” rating to DCPH stocks, setting the target price at $34 in the report published on October 22, 2019.
DCPH Stocks -12.08% Far from 50 Day Moving Average
After a stumble in the market that brought DCPH to its low price for the period of the last 52 weeks, Deciphera Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -21.90% of loss for the given period.
The stock volatility was left at 4.17%, however, within the period of a single month, the volatility rate increased by 5.85%, while the shares sank at the distance of -17.31% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +8.27% upper at the present time.
In the course of the last 5 trading sessions, DCPH went down by -17.07%, which changed the moving average for the period of 200 days to the total of +142.22% of gains for the stock in comparison to the 20-day moving average settled at $65.65. In addition, Deciphera Pharmaceuticals, Inc. saw -10.76% in overturn over the period of a single year with a tendency to cut further losses.
DCPH Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Deciphera Pharmaceuticals, Inc. (DCPH), starting from Allen Patricia L, who sold 25,000 shares at the price of $66.13 back on Jan 24. After this action, Rushing now owns 0 shares of Deciphera Pharmaceuticals, Inc., valued at $1,653,325 with the latest closing price.
Martin Daniel C., the Chief Commercial Officer of Deciphera Pharmaceuticals, Inc., sold 26,999 shares at the value of $67.18 during a trade that took place back on Jan 22, which means that Martin Daniel C. is holding 17,000 shares at the value of $1,813,709 based on the most recent closing price.
DCPH Stock Fundamentals
Based on Deciphera Pharmaceuticals, Inc. (DCPH), the company’s capital structure generated 4.69 points for debt to equity in total, while total debt to capital is set at the value of 4.48. Total debt to assets is settled at the value of 4.16 with long-term debt to equity ratio rests at -1,239.27 and long-term debt to capital is 4.45.